Status:
COMPLETED
Online Mindfulness-based Tic Reduction (Phase Two)
Lead Sponsor:
Bowdoin College
Collaborating Sponsors:
Massachusetts General Hospital
Conditions:
Tourette Syndrome
Persistent Tic Disorder
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Tourette Syndrome (TS) and Persistent Tic Disorder (PTD) are chronic and potentially disabling neurobiological conditions. Although a range of pharmacological and psychosocial treatments exists, a sig...
Eligibility Criteria
Inclusion
- be 18 years of age or older,
- possess a primary diagnosis of Tourette Syndrome or Persistent Tic Disorder,
- be fluent in English
- reside in the United States,
- either not be taking any tic suppressant medication or other psychotropic medication or be at a stable dose for 8 weeks prior to the baseline assessment and throughout the study
Exclusion
- be receiving concurrent psychotherapy for the duration of the study
- have prior extensive experience with mindfulness and/or meditation and
- have another medical or psychological condition that would prevent the individual from fully engaging in the study or require a higher level of care (e.g., suicidality).
Key Trial Info
Start Date :
November 9 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 2 2020
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT03771235
Start Date
November 9 2018
End Date
December 2 2020
Last Update
April 29 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Bowdoin College
Brunswick, Maine, United States, 04011
2
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114